Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients

被引:42
作者
Dahaba, AA
Elawady, GA
Rehak, RH
List, WF
机构
[1] Karl Franzens Univ Graz, Dept Anesthesiol & Intens Care Med, A-8036 Graz, Austria
[2] Karl Franzens Univ Graz, Dept Surg, Biomed Engn & Comp Unit, Graz, Austria
关键词
sepsis : procalcitonin; cytokines; interleukin-6; tumour necrosis factor alpha; interleukin-1; beta; continuous venovenous haemofiltration;
D O I
10.1177/0310057X0203000302
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Procalcitonin (PCT), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFalpha), and interleukin-1beta (IL-1beta) are important clinical prognostic markers in ICU septic patients. The goal of the study was to determine whether continuous venovenous haemofiltration (CVVH), using an AN69 haemofilter, leads to elimination of PCT, TNFalpha IL-6 and IL-1beta in 1.3 septic patients with multi-organ failure. At the start of haemofiltration (0), 6 and 12 hours the mean afferent plasma concentration +/-SD of PCT (10.1 +/- 9.1, 7 +/- 6, 5.9 +/- 5.7 ng/ml), IL-6 (804.6 +/- 847.6, 611.7 +/- 528.4, 575.2 +/- 539.2 pg/ml), and that of TNFalpha (4.5 +/- 2.6, 4 +/- 3.1, 3.8 +/- 2.9 pg/ml) significantly declined during CVVH. The efferent plasma concentrations were significantly lower than the corresponding afferent concentrations. PCT, IL-6 and TNFalpha were detectable in the ultrafiltrate of all patients. IL-1beta was only detectable in the plasma of eight patients and the ultrafiltrate of five patients. The plasma clearance of PCT, IL-6 and TNFalpha significantly decreased after 12 hours as a result of a decline in the adsorptive elimination of the mediators due to progressive membrane saturation. We demonstrated that if PCT, IL-6 and TNFalpha are used as clinical prognostic markers in septic patients who are treated with CVVH using an AN69 membrane, one should be aware that their plasma level could be modified by the therapy. In addition CVVH could represent an appropriate tool to remove a broad spectrum of proinflammatory mediators, if such removal is required in septic patients.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 19 条
[1]   HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION [J].
ASSICOT, M ;
GENDREL, D ;
CARSIN, H ;
RAYMOND, J ;
GUILBAUD, J ;
BOHUON, C .
LANCET, 1993, 341 (8844) :515-518
[2]   THE PATHOGENESIS OF SEPSIS [J].
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :457-469
[3]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[4]   Prediction of microbial infection and mortality in medical patients with fever:: Plasma procalcitonin, neutrophilic elastase-α1-antitrypsin, and lactoferrin compared with clinical variables [J].
Bossink, AWJ ;
Groeneveld, ABJ ;
Thijs, LG .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :398-407
[5]  
De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846
[6]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843
[7]   INFLUENCE OF AN ANTITUMOR NECROSIS FACTOR MONOCLONAL-ANTIBODY ON CYTOKINE LEVELS IN PATIENTS WITH SEPSIS [J].
FISHER, CJ ;
OPAL, SM ;
DHAINAUT, JF ;
STEPHENS, S ;
ZIMMERMAN, JL ;
NIGHTINGALE, P ;
HARRIS, SJ ;
SCHEIN, RMH ;
PANACEK, EA ;
VINCENT, JL ;
FOULKE, GE ;
WARREN, EL ;
GARRARD, C ;
PARK, G ;
BODMER, MW ;
COHEN, J ;
VANDERLINDEN, C ;
CROSS, AS ;
SADOFF, JC ;
GORECKI, J ;
DUBIN, HG ;
GARNER, C ;
KAYE, W ;
LANORE, JJ ;
MIRA, JP ;
ZIMMERMAN, J ;
DELLINGER, RP ;
TAYLOR, RW ;
DAHL, S ;
SHELLY, M ;
MORTIMER, A ;
EDWARDS, JD ;
KETT, DH ;
QUARTIN, A ;
PENA, MA ;
BAKKER, J ;
ALBERSON, TE ;
WALBY, W ;
RADCLIFFE, J ;
YOUNG, D ;
MCQUILLAM, P ;
BELLINGHAM, G ;
BURMAN, W ;
SADOFF, JS ;
YOUNG, L .
CRITICAL CARE MEDICINE, 1993, 21 (03) :318-327
[8]  
GOLDFARB S, 1994, J AM SOC NEPHROL, V5, P228
[9]   Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration [J].
Heering, P ;
Morgera, S ;
Schmitz, FJ ;
Schmitz, G ;
Willers, R ;
Schultheiss, HP ;
Strauer, BE ;
Grabensee, B .
INTENSIVE CARE MEDICINE, 1997, 23 (03) :288-296
[10]   Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients [J].
Herrmann, W ;
Ecker, D ;
Quast, S ;
Klieden, M ;
Rose, S ;
Marzi, I .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (01) :41-46